Survival benefit of deceased donor kidney transplantation versus continued dialysis
A more visual summary of the target trial emulation and relevant context (just 7 images to look at!). Infographics by Anca Stefan and Cristina Popa
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
This week, we will discuss the best schedule for tapering steroids in adult patients with podocytopathies (MCD/FSGS).
This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
A more visual summary of the target trial emulation and relevant context (just 7 images to look at!). Infographics by Anca Stefan and Cristina Popa
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 en el riñón trasplantado? Revisa el resumen visual creado por Janany Sabescumar
A thread on the most relevant part of the chat on tolerance induction in HLA-matched transplant with donor hematopoietic stem cells (MDR-101). Thread by Akshaya Jayachandran.
What is the effect of microvascular inflammation on kidney allografts? Checkout the crisp VA by NSMC faculty Dr Divya Bajpai.
El Resumen Visual
El Ferzartamab muestra resultados prometedores en el tratamiento del rechazo mediado por anticuerpos en trasplantados renales. En este ensayo clínico fase 2 aleatorizado, se evaluó el perfil de seguridad y los resultados secundarios a las 24 semanas.
¿Podría este anticuerpo anti-CD38 ser la nueva opción terapéutica revolucionaria para prevenir la pérdida del injerto mediada por anticuerpos? Observa el resumen visual realizado por el pasante del NSMC, Dr. Shahin Mohammed.
Can felzartamab represent a new hope for antibody-mediated rejection? Check out the visual abstract by Shahin Mohammed
Hypothermia or Machine Perfusion in Kidney Donors (Malinoski, NEJM 2023)
An automated histological classification system for precision diagnostics of kidney allografts (Yoo, Nature Medicine 2023)
Another sterlling visual abstract from Milagros Flores
This week, nephrologists hope they found the key to no-dialysis-land, where kindness and detailed, multistep interventions make the path to kidney transplant much easier. This was foreseen in our Freely Filtered episode and disputed during #KidneyWK 2023 late-breaking clinical trials session. Still, when it comes to RCTs’ results, will it be Deja Vu or a happy ending?
Is intravenous fluid therapy with a balanced crystalloid solution better than saline for patients receiving a deceased donor kidney transplant? Check out the BEST-FLUID VA by NSMC Intern Anitha Swami